

BDR Pharma partners with Varenyam Healthcare to revolutionise Anaesthesia practices in India

31 May 2022 | News

Sugmadex is set to be the game changer in the segment of reversal agents in the modern day surgery



Mumbai-based BDR Pharmaceuticals and Varenyam Healthcare have announced the launch of Sugmadex, bringing to India a first of its kind drug in over 10 years with novel β -cyclodextrin neuromuscular block (NMB) reversal properties.

Sugmadex (Sugammadex 100mg/ml) is a pioneer in Anaesthesia drugs offering safe, rapid and complete reversal of shallow, moderate and deep neuromuscular block (NMB), resulting in the removal of anaesthesia effect on the body.

Currently available reversal agents cannot reverse profound NMB & quite often result in postoperative respiratory complications. The clinical use of Sugmadex is a breakthrough that promises to eliminate many of the shortcomings in current anaesthetic practice. Sugmadex is available as 2 ml & 5 ml single-dose vials.

Commenting on the launch, Raheel Shah, Director Business Development on behalf of BDR Pharmaceuticals said, "The results collated from the Indian trials on patients promise to be advantageous for the users lacking any side effects. Sugmadex is set to be the game changer in the segment of reversal agents in the modern day surgery. This product is testament to our objective of bringing innovation with the introduction of Novel drugs which were not present in the domestic market previously."